LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Ligand Pharmaceuticals Incorporated

3911 Sorrento Valley Boulevard
Suite 110
San Diego, CA 92121
United States
858-550-7500
http://www.ligand.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Mr. John L. HigginsCEO & Exec. Director967.36k469.5k1970
Mr. Matthew W. FoehrPres & COO697.43k2.6M1973
Mr. Matthew KorenbergExec. VP of Fin. & CFO505.12kN/A1975
Mr. Charles S. BerkmanSr. VP, Gen. Counsel & Sec.471.86k2.08M1969
Mr. Todd PettingillDirector of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Corporate Governance

Ligand Pharmaceuticals Incorporated’s ISS Governance QualityScore as of November 1, 2018 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.